Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01

A Multicenter Analysis of Definitive (Chemo)Radiotherapy With or Without Chemotherapy for Patients With Esophageal Cancer - 3JECROG-R01

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03298204

Enrollment

2762

Registered

2017-10-02

Start date

2017-06-01

Completion date

2018-02-28

Last updated

2019-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemoradiation, Chemotherapy Effect, Esophagus Cancer, Radiotherapy Side Effect

Brief summary

The aim of this observational study is to retrospectively collect survival data for 3000 primary esophageal cancer patients from multicenter between January 2000 to present. Based on a Cox model, we want to develope a nomogram that predicts local recurrence, distant metastases, and survival for patients treated with radiotherapy or chemoradiotherapy with or without chemotherapy.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed squamous cell carcinoma, adenocarcinoma of the esophageal or esophagogastric junction Unresectable or potentially resectable tumor (cT3-4N0-1M0-M1b, without visceral metastasis, according to AJCC 6th) based on standard primary staging by EUS and CT * Age\>18 years * No distant metastasis other than supraclavicular lymph nodes * No prior history of thoracic radiation * Patients must have normal organ and marrow function as defined below: Leukocytes: greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits

Exclusion criteria

* Patients with other cancer history except cervical carcinoma in situ and non-malignant melanoma skin cancer during 5 years before diagnosis of esophageal cancer * Pregnant or lactating females * Contraindication for radiotherapy or chemotherapy

Design outcomes

Primary

Measure	Time frame
Overall survival	1 year

Secondary

Measure	Time frame
Progress free survival	1 year
Locoregional recurrence free survival	1 year
Distant metastasis free survival	1 year

Countries

China

Outcome results